40 results
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
a Material Adverse Effect if not otherwise excluded by another clause of this definition), or (ix) any pandemic, public health event, outbreak of disease
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of Coherus’ competitive position
8-K
EX-99.1
s9ty7bmg
27 Oct 23
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
3p1 fo7z8pxo7ste
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
424B3
8pzii098pkd847gstn3f
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
gxi02 k0gc
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
15soj799iz nj9oishel
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
z380as
16 Jun 23
Business combination disclosure
8:08am
425
cy4h8r
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
i8fkmbtl ci0e
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
424B5
6gg1gwilnxwq0 gf
17 May 23
Prospectus supplement for primary offering
4:02pm
424B5
hw8mz
16 May 23
Prospectus supplement for primary offering
6:07am
8-K
EX-99.1
jl5n533 19gsa96i
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
jqwsd 1mtx0
8 Nov 22
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
4:01pm